Hengsai Biotechnology Wins the 13th China Innovation and Entrepreneurship Competition (Guangdong Region)

关于恒赛生物

Founded in 2018, Hengsai Bio is a scientific and technological innovative enterprise and national high-tech enterprise dedicated to the research, development and industrialization of dendritic cell vaccines (DC vaccines). The company has successfully constructed the Eco-DCVax platform, aiming to break down the technical barriers to industrialization and develop global First-in-Class high-quality DC vaccine products with independent property rights that are safe, efficient and convenient to administer. The developed product, therapeutic dendritic cell vaccine, provides a new approach and strategy for the treatment of relapsed and refractory tumors, chronic viral infections, autoimmune diseases and other diseases that are in urgent need of effective clinical treatments.

恒赛生物上海研发中心2021年投入使用，中山研发中心2024年10月正式启用，大型研发/生产基地正在建设中。公司首发管线KSD-101已顺利完成中美双报，获得美国食品药品监督管理局（FDA）授予新药临床试验（IND）许可，为我国首款获得美国FDA IND批件的原创树突细胞疫苗(DC疫苗)产品。公司现已和多家国内外科研机构和三甲医院建立稳定的合作关系，开展临床研究和技术合作，以全面验证DC疫苗的临床安全性和有效性。